Active With Me Inc. Sample Contracts

Rasna Therapeutics Inc. – 12% CONVERTIBLE PROMISSORY NOTE DUE October 19 2019 (February 14th, 2019)

THIS CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued Notes of Rasna Therapeutics, Inc., a Nevada corporation, (the “Borrower”), having its principal place of business at 420 Lexington Avenue, Suite 2525, New York, New York 10170, due October 19, 2019 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).

Rasna Therapeutics Inc. – 12% CONVERTIBLE PROMISSORY NOTE DUE AUGUST 8, 2019 (August 9th, 2018)

THIS CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued Notes of Rasna Therapeutics, Inc., a Nevada corporation, (the “Borrower”), having its principal place of business at 420 Lexington Avenue, Suite 2525, New York, New York 10170, due August 8, 2019 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).

Rasna Therapeutics Inc. – RASNA THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES (April 6th, 2018)
Rasna Therapeutics Inc. – RASNA THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES (April 6th, 2018)
Rasna Therapeutics Inc. – About Dr. Brunangelo Falini, M.D. Brunangelo Falini is the head of the Institute of Hematology and Hemopoietic Stem Cell Transplantation at the University of Perugia, Perugia, Italy. His research activity has mainly focused on the genetic characterization of lymphomas and leukemias using monoclonal antibodies and, more recently, NGS technologies. He led the research group who discovered NPM1 mutations in AML in 2005 and the BRAF-V600E mutation in hairy cell leukemia in 2011. Both these seminal discoveries have already translated into a better diagnosis and therapy of patients affected by these (January 4th, 2018)

Treatment with Act D at 15 µg/kg/day for 5 days every 28 days (which defines one cycle) was well tolerated with major toxicity limited only to oral mucositis.

Rasna Therapeutics Inc. – SECURITIES PURCHASE AGREEMENT (August 31st, 2017)

This Securities Purchase Agreement (this “Agreement”) is dated as of August __, 2017, between Rasna Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Rasna Therapeutics Inc. – EXECUTIVE EMPLOYMENT AGREEMENT (June 30th, 2017)

This Executive Employment Agreement (the “Agreement”) is entered into effective May 24, 2017 (the “Effective Date”), by and between Shailubhai Kunwar (the “Executive”) and Rasna Therapeutics, Inc. (the “Company”).

Rasna Therapeutics Inc. – Rasna Therapeutics, Inc. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (March 14th, 2017)

The following unaudited pro forma condensed combined financial statements give effect to the Transactions (as defined below) which were consummated on August 15, 2016, pursuant to the Transaction Documents by and between the parties set out below the Transactions and gives effect to the equity offering. The Transactions are inclusive of the following:

Rasna Therapeutics Inc. – CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (March 14th, 2017)
Rasna Therapeutics Inc. – SECURITIES PURCHASE AGREEMENT (December 27th, 2016)

This Securities Purchase Agreement (this “Agreement”) is dated as of December __, 2016, between Rasna Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Rasna Therapeutics Inc. – CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (November 17th, 2016)
Rasna Therapeutics Inc. – Rasna Therapeutics, Inc. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (November 17th, 2016)

The following unaudited pro forma condensed combined financial statements give effect to the Transactions (as defined below) which were consummated on August 15, 2016, pursuant to the Transaction Documents by and between the parties set out below the Transactions and gives effect to the equity offering. The Transactions are inclusive of the following:

Active With Me Inc. – AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ACTIVE WITH ME, INC., A Nevada corporation (September 26th, 2016)

Active With Me, Inc., a corporation organized and existing under the Nevada Revised Statutes (the “Corporation”), does hereby certify:

Active With Me Inc. – AGREEMENT OF CONVEYANCE, TRANSFER AND ASSIGNMENT OF ASSETS AND ASSUMPTION OF OBLIGATIONS (August 17th, 2016)

This Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (“Transfer and Assumption Agreement”) is made as of  August 15, 2016, by Active With Me, Inc., a Nevada corporation (“Assignor”), and Active With Me Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Assignor (“Assignee”).

Active With Me Inc. – Active With Me, Inc. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (August 17th, 2016)

The following unaudited pro forma condensed combined financial statements give effect to the Transactions (as defined below) which were consummated on August 15, 2016, pursuant to the Transaction Documents by and between the parties set out below the Transactions and gives effect to the equity offering.  The Transactions are inclusive of the following:

Active With Me Inc. – AMENDED AND RESTATED BY-LAWS OF ACTIVE WITH ME, INC. (a Nevada Corporation) Adopted as of August 12, 2016 (August 17th, 2016)
Active With Me Inc. – STOCK PURCHASE AGREEMENT (August 17th, 2016)

THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of August 15, 2016, is made by and between ACTIVE WITH ME, Inc. a Nevada corporation (“Seller”), and each of the individuals listed under the heading “Buyers” on the signature page hereto (collectively, “Buyers”).

Active With Me Inc. – AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (August 17th, 2016)

THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this “Agreement”) is made and entered into on May 17, 2016 by and among Rasna Therapeutics, Inc., a Delaware corporation (“Parent”), Falconridge Holdings Limited, a corporation organized under the laws of the British Virgin Islands (“Falconridge”), which is a wholly-owned subsidiary of Parent, and Arna Therapeutics Limited, a corporation formed under the laws of the British Virgin Islands (the “Company”).

Active With Me Inc. – ACTIVE WITH ME, INC. 2016 EQUITY INCENTIVE PLAN (August 17th, 2016)
Active With Me Inc. – AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (August 17th, 2016)

THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this “Agreement”) is made and entered into on August 15, 2016 by and among Active With Me, Inc., a Nevada corporation (“Parent”), Rasna Acquisition Corp., a Delaware corporation (“Acquisition Corp.”), which is a wholly-owned subsidiary of Parent, and Rasna Therapeutics, Inc., a Delaware corporation (the “Company”).

Active With Me Inc. – BYLAWS of ACTIVE WITH ME INC. (the "Corporation") (September 11th, 2013)